ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ANTIGEN EXPRESSION;
ARTICLE;
CANCER SURVIVAL;
CELL SPECIFICITY;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG TARGETING;
GLIOMA;
HISTOPATHOLOGY;
HUMAN;
HUMAN CELL;
IN VITRO STUDY;
IN VIVO STUDY;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
RISK ASSESSMENT;
RISK FACTOR;
RISK REDUCTION;
SIGNAL TRANSDUCTION;
SURVIVAL RATE;
T LYMPHOCYTE;
CENTRAL NERVOUS SYSTEM NEOPLASMS;
EPIDERMAL GROWTH FACTOR RECEPTOR;
GLIOBLASTOMA;
IMMUNOTHERAPY;
T-LYMPHOCYTES;
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
M.C. Milone, J.D. Fish, and C. Carpenito Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Mol Ther 17 2009 1453 1464
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
R. Nishikawa, X.D. Ji, and R.C. Harmon A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proc Natl Acad Sci USA 91 1994 7727 7731
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma
R.A. Morgan, L.A. Johnson, and J.L. Davis Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma Hum Gene Ther 23 2012 1043 1053
Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen
M. Ohno, A. Natsume, and K. Ichiro Iwami Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen Cancer Sci 101 2010 2518 2524
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
R.A. Morgan, J.C. Yang, and M. Kitano Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 18 2010 843 851
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase i clinical trial
R. Brentjens, R. Yeh, and Y. Bernal Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial Mol Ther 18 2010 666 668
